Search

Your search keyword '"Barbarot S"' showing total 1,095 results
Start Over Author "Barbarot S"
1,095 results on '"Barbarot S"'

2. Promoting clinical research in community-based practice: Threats and opportunities

Author

Poizeau, F., primary, Maruani, A., additional, Staumont-Sallé, D., additional, Jouan, N., additional, Ly, S., additional, Schollhammer, M., additional, Reverte, M., additional, Dibao-Dina, C., additional, Duong, T.-A., additional, Matard, B., additional, Penso-Assathiany, D., additional, Dupuy, A., additional, Carriot, M., additional, Seï, J.-F., additional, Corgibet, F., additional, Guillot, B., additional, Barbarot, S., additional, Leducq, S., additional, Bertolotti, A., additional, Tannous, J., additional, Chaby, G., additional, Jullien, D., additional, Pépin, E., additional, Quéreux, G., additional, Beylot-Barry, M., additional, and Chosidow, O., additional

Published
2024
Full Text
View/download PDF

5. Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Author

Thyssen, J. P., primary, Thaçi, D., additional, Bieber, T., additional, Gooderham, M., additional, de Bruin‐Weller, M., additional, Soong, W., additional, Kabashima, K., additional, Barbarot, S., additional, Luna, P. C., additional, Xu, J., additional, Hu, X., additional, Liu, Y., additional, Raymundo, E. M., additional, Calimlim, B. M., additional, Nduaka, C., additional, Gamelli, A., additional, and Simpson, E. L., additional

Published
2023
Full Text
View/download PDF

6. Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014–2021 French Ouest DataHub

Author

Mauguen, C., primary, Maruani, A., additional, Barbarot, S., additional, Abasq, C., additional, Martin, L., additional, Herbert, J., additional, Goronflot, T., additional, Gourraud, P.-A., additional, Happe, A., additional, Descatha, A., additional, Chrétien, J.-M., additional, Beuchée, A., additional, Adamski, H., additional, Dupuy, A., additional, Bouzillé, G., additional, Oger, E., additional, and Droitcourt, C., additional

Published
2023
Full Text
View/download PDF

7. Efficacité de l’upadacitinib versus dupilumab dans la dermatite atopique modérée à sévère : analyse du temps de maintien de réponse dans l’étude Heads Up

Author

Blauvelt, A., primary, Silverberg, J.I., additional, Eyerich, K., additional, Irvine, A.D., additional, De Bruin-Weller, M., additional, Liu, Y., additional, Raymundo, E., additional, Wegzyn, C., additional, Platt, A., additional, Calimlim, B., additional, Barbarot, S., additional, and Thyssen, J., additional

Published
2023
Full Text
View/download PDF

9. Management of tinea capitis in children following the withdrawal of griseofulvin from the French market: A fast-track algorithm proposed by the Center of Evidence of the French Society of Dermatology

Author

Maruani, A., primary, Barbarot, S., additional, Gangneux, J.P., additional, Caseris, M., additional, Moreau, C., additional, Brun, S., additional, Botterel, F., additional, Menotti, J., additional, Toubiana, J., additional, Chouchana, L., additional, Beylot-Barry, M., additional, Dupin, N., additional, Guillot, B., additional, and Chosidow, O., additional

Published
2022
Full Text
View/download PDF

10. Quality of life of children with capillary malformations of the lower limbs: Evolution and associated factors. Data from the French national paediatric cohort, CONAPE

Author

Robert, J., primary, Marchand, A., additional, Mazereeuw-Hautier, J., additional, Boccara, O., additional, Martin, L., additional, Chiaverini, C., additional, Beneton, N., additional, Vabres, P., additional, Balguerie, X., additional, Plantin, P., additional, Bessis, D., additional, Barbarot, S., additional, Dadban, A., additional, Droitcourt, C., additional, Samimi, M., additional, Morel, B., additional, Caille, A., additional, Maruani, A., additional, and Leducq, S., additional

Published
2022
Full Text
View/download PDF

15. Traitements combinés biothérapies – traitements systémiques classiques chez les enfants atteints de psoriasis sévère. Données en vie courante à partir des cohortes BiPe, et enquête de pratiques chez les dermatologues pédiatres français et italiens

Author

Mahé, E., primary, Beauchet, A., additional, Hadj-Rabia, S., additional, Mazereeuw-Hautier, J., additional, Mallet, S., additional, Phan, A., additional, Severino Freire, M., additional, Boralévi, F., additional, Aubert, H., additional, Barthélémy, H., additional, Girard, C., additional, Martin, L., additional, Piram, M., additional, Barbarot, S., additional, Balguérie, X., additional, Zitouni, J., additional, Phan, C., additional, and Di Lernia, V., additional

Published
2022
Full Text
View/download PDF

16. VEGF, facteur tissulaire, marqueurs de la coagulation et de la fibrinolyse dans les malformations vasculaires à flux lent : étude prospective et impact du sirolimus

Author

Moineau, A.G., primary, Maruani, A., additional, Boccara, O., additional, Mazereeuw-Hautier, J., additional, Leducq, S., additional, Bessis, D., additional, Guibaud, L., additional, Vabres, P., additional, Mallet, S., additional, Barbarot, S., additional, Chiaverini, C., additional, Droitcourt, C., additional, Bursztejn, A.C., additional, Lengelle, C., additional, Woillard, J.B., additional, Herbreteau, D., additional, Le Touze, A., additional, Binet, A., additional, Morel, B., additional, Bourgoin, H., additional, Gissot, V., additional, Giraudeau, B., additional, Gruel, Y., additional, Tavernier, E., additional, and Rollin, J., additional

Published
2022
Full Text
View/download PDF

17. Efficacité et tolérance des inhibiteurs de Janus kinase dans le traitement de la dermatite atopique modérée à sévère de l’adulte réfractaire à d’autres systémiques: expérience en vraie vie

Author

Vanlerberghe, J., primary, Dezoteux, F., additional, Martin, C., additional, Jachiet, M., additional, Soria, A., additional, Tétart, F., additional, Modeste-Duval, A.B., additional, Bursztejn, A.C., additional, Misery, L., additional, Aubin, F., additional, Lasek, A., additional, Leleu, C., additional, Du Thanh, A., additional, Pasteur, J., additional, Pralong, P., additional, Nosbaum, A., additional, Droitcourt, C., additional, Viguier, M., additional, Tauber, M., additional, Seneschal, J., additional, Barbarot, S., additional, and Staumont-Sallé, D., additional

Published
2022
Full Text
View/download PDF

18. Efficacité d’une intervention d’éducation thérapeutique courte par une infirmière dans la dermatite atopique de l’enfant. Étude randomisée contrôlée multicentrique

Author

Barbarot, S., primary, Aubert, H., additional, Vibet, M.A., additional, Leray, M., additional, Elan, F., additional, Meneron, L., additional, Stalder, J.F., additional, Mazereeuw-Hautier, J., additional, Phan, A., additional, Droitcourt, C., additional, Bursztejn, A.C., additional, Boralévi, F., additional, Chiaverini, C., additional, Raison Peyron, N., additional, Lasek, A., additional, Misery, L., additional, Abasq, C., additional, and Mallet, S., additional

Published
2022
Full Text
View/download PDF

20. Étude descriptive multicentrique des schémas d’adaptation en cas de réponse inadéquate au dupilumab dans la dermatite atopique en France

Author

Strizzolo, R., primary, Soria, A., additional, Jachiet, M., additional, Tauber, M., additional, Seneschal, J., additional, Clément, A., additional, Staumont-Sallé, D., additional, Barbarot, S., additional, Raison Peyron, N., additional, Viguier, M., additional, Mallet, S., additional, and Du Thanh, A., additional

Published
2022
Full Text
View/download PDF

21. European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations

Author

Wollenberg, A., primary, Kinberger, M., additional, Arents, B., additional, Aszodi, N., additional, Avila Valle, G., additional, Barbarot, S., additional, Bieber, T., additional, Brough, H.A., additional, Calzavara Pinton, P., additional, Christen‐Zäch, S., additional, Deleuran, M., additional, Dittmann, M., additional, Dressler, C., additional, Fink‐Wagner, A.H., additional, Fosse, N., additional, Gáspár, K., additional, Gerbens, L., additional, Gieler, U., additional, Girolomoni, G., additional, Gregoriou, S., additional, Mortz, C.G., additional, Nast, A., additional, Nygaard, U., additional, Redding, M., additional, Rehbinder, E.M., additional, Ring, J., additional, Rossi, M., additional, Serra‐Baldrich, E., additional, Simon, D., additional, Szalai, Z.Z., additional, Szepietowski, J.C., additional, Torrelo, A., additional, Werfel, T., additional, and Flohr, C., additional

Published
2022
Full Text
View/download PDF

22. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries

Author

Vermeulen, FM, Gerbens, LAA, Bosma, AL, Apfelbacher, CJ, Irvine, AD, Arents, BWM, Barbarot, S, Deleuran, M, Eichenfield, LF, Manca, A, Schmitt, J, Vestergaard, C, Wall, D, Weidinger, S, Middelkamp‐Hup, MA, Spuls, PI, Flohr, C, and Taskforce, the International TREAT Registry

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Prevention, Skin, Adult, Advisory Committees, Aftercare, Child, Consensus, Datasets as Topic, Dermatitis, Atopic, Dermatologic Agents, Humans, Phototherapy, Prospective Studies, Registries, Severity of Illness Index, Treatment Outcome, International TREAT Registry Taskforce, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundComparative, real-life and long-term evidence on the effectiveness and safety of phototherapy and systemic therapy in moderate-to-severe atopic eczema (AE) is limited. Such data must come from well-designed prospective patient registries. Standardization of data collection is needed for direct comparisons and data pooling.ObjectivesTo reach a consensus on how and when to measure the previously defined domain items of the TREatment of ATopic eczema (TREAT) Registry Taskforce core dataset for research registries for paediatric and adult patients with AE.MethodsProposals for the measurement instruments were based on recommendations of the Harmonising Outcome Measures for Eczema (HOME) initiative, the existing AE database of TREATgermany, systematic reviews of the literature and expert opinions. The proposals were discussed at three face-to-face consensus meetings, one teleconference and via e-mail. The frequency of follow-up visits was determined by an expert survey.ResultsA total of 16 experts from seven countries participated in the 'how to measure' consensus process and 12 external experts were consulted. A consensus was reached for all domain items on how they should be measured by assigning measurement instruments. A minimum follow-up frequency of initially 4 weeks after commencing treatment, then every 3 months while on treatment and every 6 months while off treatment was defined.ConclusionsThis core dataset for national AE research registries will aid in the comparability and pooling of data across centres and country borders, and enables international collaboration to assess the long-term effectiveness and safety of phototherapy and systemic therapy used in patients with AE. What's already known about this topic? Comparable, real-life and long-term data on the effectiveness and safety of phototherapy and systemic therapy in patients with atopic eczema (AE) are needed. There is a high diversity of outcomes and instruments used in AE research, which require harmonization to enhance comparability and allow data pooling. What does this study add? Our taskforce has reached international consensus on how and when to measure core domain items for national AE research registries. This core dataset is now available for use by researchers worldwide and will aid in the collection of unified data. What are the clinical implications of this work? The data collected through this core dataset will help to gain better insights into the long-term effectiveness and safety of phototherapy and systemic therapy in AE and will provide important information for clinical practice. Standardization of such data collection at the national level will also allow direct data comparisons and pooling across country borders (e.g. in the analysis of treatment-related adverse events that require large patient numbers).

Published
2019

23. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

Author

Wollenberg, A., primary, Kinberger, M., additional, Arents, B., additional, Aszodi, N., additional, Avila Valle, G., additional, Barbarot, S., additional, Bieber, T., additional, Brough, H.A., additional, Calzavara Pinton, P., additional, Christen‐Zäch, S., additional, Deleuran, M., additional, Dittmann, M., additional, Dressler, C., additional, Fink‐Wagner, A.H., additional, Fosse, N., additional, Gáspár, K., additional, Gerbens, L., additional, Gieler, U., additional, Girolomoni, G., additional, Gregoriou, S., additional, Mortz, C.G., additional, Nast, A., additional, Nygaard, U., additional, Redding, M., additional, Rehbinder, E.M., additional, Ring, J., additional, Rossi, M., additional, Serra‐Baldrich, E., additional, Simon, D., additional, Szalai, Z.Z., additional, Szepietowski, J.C., additional, Torrelo, A., additional, Werfel, T., additional, and Flohr, C., additional

Published
2022
Full Text
View/download PDF

25. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries

Author

Gerbens, LAA, Apfelbacher, CJ, Irvine, AD, Barbarot, S, Booij, RJ, Boyce, AE, Deleuran, M, Eichenfield, LF, Hof, MH, Middelkamp‐Hup, MA, Roberts, A, Schmitt, J, Vestergaard, C, Wall, D, Weidinger, S, Williamson, PR, Flohr, C, Spuls, PI, and Taskforce, the international TREAT Registry

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Cancer, Clinical Research, Advisory Committees, Consensus, Delphi Technique, Dermatitis, Atopic, Humans, Immunologic Factors, International Cooperation, Photochemotherapy, Photosensitizing Agents, Registries, Stakeholder Participation, Treatment Outcome, international TREAT Registry Taskforce, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BACKGROUND:Evidence of immunomodulatory therapies to guide clinical management of atopic eczema (AE) is scarce, despite frequent and often off-label use. Patient registries provide valuable evidence for the effects of treatments under real-world conditions that can inform treatment guidelines, give the opportunity for health economic evaluation and the evaluation of quality of care, as well as pharmacogenetic and dynamic research, which cannot be adequately addressed in clinical trials. OBJECTIVES:The TREatment of ATopic eczema (TREAT) Registry Taskforce aims to seek international consensus on a core set of domains and items ('what to measure') for AE research registries, using a Delphi approach. METHODS:Participants from six stakeholder groups were included: doctors, nurses, nonclinical researchers, patients, industry and regulatory body representatives. The eDelphi comprised three sequential online rounds, requesting participants to rate the importance of each proposed domain item. Participants could add domain items to the proposed list in round 1. A final consensus meeting was held to ratify the core set. RESULTS:Participants (n = 479) from 36 countries accessed the eDelphi platform, of whom 86%, 79% and 74% completed rounds 1, 2 and 3, respectively. At the face-to-face consensus meeting attended by 42 participants the final core set was established containing 19 domains with 69 domain items (49 baseline and 20 follow-up items). CONCLUSIONS:This core set of domains and items to be captured by national AE systemic therapy registries will standardize data collection and thereby allow direct comparability across registries and facilitate data pooling between countries. Ultimately, it will provide greater insight into the effectiveness, safety and cost-effectiveness of photo- and systemic immunomodulatory therapies.

Published
2019

26. Perceived clinical severity of atopic dermatitis in children: comparison between patients’ and parents’ evaluation

Author

Mahe, E., primary, Shourick, J., additional, Mallet, S., additional, Abasq, C., additional, Bursztejn, A‐C., additional, Sampogna, F., additional, Bodemer, C., additional, Boralevi, F., additional, Barbarot, S., additional, Lasek, A., additional, Merhand, S., additional, Taïeb, C., additional, and Ezzedine, K., additional

Published
2022
Full Text
View/download PDF

27. Blépharo-conjonctivites sous dupilumab : recommandations du groupe CEDRE. Dermatite atopique, conjonctivites et dupilumab : quelle prise en charge ?

Author

Doan, S., primary, Arnould, L., additional, Febvay, C., additional, Fournié, P., additional, Gueudry, J., additional, Labalette, P., additional, Ouilhon, C., additional, Tran, T.-H.-C., additional, Vabres, B., additional, Barbarot, S., additional, Bouaziz, J.-D., additional, Du-Thanh, A., additional, Jachiet, M., additional, Seneschal, J., additional, Soria, A., additional, Staumont-Sallé, D., additional, Baudouin, C., additional, and Mortemousque, B., additional

Published
2022
Full Text
View/download PDF

30. Phototherapy for atopic dermatitis: A survey of European practice.

Author

Steyn, M., Gerbens, L. A. A., Spuls, P. I., Mashayekhi, S., Deleuran, M., Barbarot, S., Wollenberg, A., Ferguson, J., Ibbotson, S., and Flohr, C.

Subjects
ATOPIC dermatitis, PHOTOTHERAPY, CHILD patients, PHOTOCHEMOTHERAPY, RANDOMIZED controlled trials
Abstract

Background: Phototherapy is used to treat atopic dermatitis (AD). Evidence for its efficacy, impact on quality of life, cost‐effectiveness and short‐ and long‐term safety with real‐life usage is weak. Objectives: We established a taskforce to examine how phototherapy is currently being used as a treatment for AD across the United Kingdom and Europe to inform our understanding and guide future research into management of patients with AD using UV‐based phototherapies. Methods: An anonymous electronic multiple‐response survey exploring phototherapy prescribing practices and experience of phototherapy modalities was developed by the study authors and sent to members of phototherapy networks from the United Kingdom and Europe. Responses were received between February and July 2021. Results: About 144 respondents from 27 European countries completed the survey. NBUVB was the most widely used [n = 138 (96%)]. Home‐based NBUVB was available in 8/27 countries (25/144 respondents, 17%). Oral psoralen‐UVA (PUVA) was more widely available than bath PUVA (n = 106, 74% vs. n = 60, 42%) and used mainly in adult patients. 49/144 (34%) of respondents had access to UVA1. Phototherapy would be considered instead of systemic treatment in 96% of adults and 82% of children for NBUVB, versus 40% of adults and 3% of children for PUVA. Starting doses, standard dosing increments, length of treatment courses, lifetime limits for treatments and thresholds for performing annual skin assessments varied between responders. Conclusions: NBUVB was the most widely used phototherapy for AD in adult and paediatric patients, while PUVA and UVA1 were less used. Prescribing practices varied considerably, highlighting the lack of consensus practice in many different aspects of phototherapy for the treatment of AD in children and adults. This indicates that further studies are required to determine optimal phototherapeutic regimens for AD and informs our understanding of parameters that should be included in future high‐quality randomized controlled trials (RCT) of phototherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Teignes de l’enfant : algorithme de prise en charge après l’arrêt de la commercialisation de la griséofulvine en France

Author

Barbarot, S., primary, Maruani, A., additional, Gangneux, J.-P., additional, Caseris, M., additional, Moreau, C., additional, Brun, S., additional, Botterel, F., additional, Menotti, J., additional, Toubiana, J., additional, Chouchana, L., additional, Beylot-Barry, M., additional, Dupin, N., additional, Guillot, B., additional, and Chosidow, O., additional

Published
2021
Full Text
View/download PDF

32. Feelings of guilt in parents of children with atopic dermatitis

Author

Bursztejn, A.C., primary, Shourick, J., additional, Bodemer, C., additional, Lasek, A., additional, Mahé, E., additional, Merhand, S., additional, Sampogna, F., additional, Taïeb, C., additional, Boralevi, F., additional, Ezzedine, K., additional, Barbarot, S., additional, Mallet, S., additional, and Abasq, C., additional

Published
2021
Full Text
View/download PDF

34. Position statement on the role of nurses in therapeutic patient education in atopic dermatitis

Author

Thormann, K., primary, Aubert, H., additional, Barbarot, S., additional, Britsch‐Yilmaz, A., additional, Chernyshov, P., additional, Deleuran, M., additional, El‐Hachem, M., additional, de Groot, J., additional, Heratizadeh, A., additional, Raymakers, F., additional, Stalder, J.F., additional, Wollenberg, A., additional, and Simon, D., additional

Published
2021
Full Text
View/download PDF

36. Acute acral eruptions in children during the COVID-19 pandemic: Characteristics of 103 children and their family clusters

Author

Hubiche, T., primary, Phan, A., additional, Leducq, S., additional, Rapp, J., additional, Fertitta, L., additional, Aubert, H., additional, Barbarot, S., additional, Chiaverini, C., additional, Giraudeau, B., additional, Lasek, A., additional, Mallet, S., additional, Labarelle, A., additional, Piram, M., additional, McCuaig, C., additional, Martin, L., additional, Monitor, L., additional, Nicol, I., additional, Bissuel, M., additional, Bellissen, A., additional, Jullien, D., additional, Lesort, C., additional, Vabres, P., additional, and Maruani, A., additional

Published
2021
Full Text
View/download PDF

37. Non‐acral skin manifestations during the COVID‐19 epidemic: COVIDSKIN study by the French Society of Dermatology

Author

Guelimi, R., primary, Salle, R., additional, Dousset, L., additional, Assier, H., additional, Fourati, S., additional, Bhujoo, Z., additional, Barbarot, S., additional, Boulard, C., additional, Cazanave, C., additional, Colin, A., additional, Kostrzewa, E., additional, Lesort, C., additional, Levy Roy, A., additional, Lombart, F., additional, Marco Bonnet, J., additional, Marty, L., additional, Monfort, J.B., additional, Riffaud, L., additional, Samimi, M., additional, Tardieu, M., additional, Sbidian, E., additional, Wolkenstein, P., additional, Le Cleach, L., additional, and Beylot‐Barry, M., additional

Published
2021
Full Text
View/download PDF

38. Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts

Author

Ring, J., primary, Worm, M., additional, Wollenberg, A., additional, Thyssen, J.P., additional, Jakob, T., additional, Klimek, L., additional, Bangert, C., additional, Barbarot, S., additional, Bieber, T., additional, Bruin‐Weller, M.S., additional, Chernyshov, P.V., additional, Christen‐Zaech, S., additional, Cork, M., additional, Darsow, U., additional, Flohr, C., additional, Fölster‐Holst, R., additional, Gelmetti, C., additional, Gieler, U., additional, Gutermuth, J., additional, Heratizadeh, A., additional, Hijnen, D.J., additional, Kobyletzki, L.B., additional, Kunz, B., additional, Paul, C., additional, De Raeve, L., additional, Seneschal, J., additional, Simon, D., additional, Spuls, P.I., additional, Stalder, J.F., additional, Svensson, A., additional, Szalai, Z., additional, Taieb, A., additional, Torrelo, A., additional, Trzeciak, M., additional, Vestergaard, C., additional, Werfel, T., additional, Weidinger, S., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

40. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics

Author

Thyssen, J.P., primary, Vestergaard, C., additional, Barbarot, S., additional, de Bruin‐Weller, M.S., additional, Bieber, T., additional, Taieb, A., additional, Seneschal, J., additional, Cork, M.J., additional, Paul, C., additional, Flohr, C., additional, Weidinger, S., additional, Trzeciak, M., additional, Werfel, T., additional, Heratizadeh, A., additional, Darsow, U., additional, Simon, D., additional, Torrelo, A., additional, Chernyshov, P.V., additional, Stalder, J.‐F., additional, Gelmetti, C., additional, Szalai, Z., additional, Svensson, Å., additional, von Kobyletzki, L.B., additional, De Raeve, L., additional, Fölster‐Holst, R., additional, Christen‐Zaech, S., additional, Hijnen, D.J., additional, Gieler, U., additional, Gutermuth, J., additional, Bangert, C., additional, Spuls, P.I., additional, Kunz, B., additional, Ring, J., additional, Wollenberg, A., additional, and Deleuran, M., additional

Published
2021
Full Text
View/download PDF

43. The Patient‐Oriented Scoring of Atopic Dermatitis and SCORAD in young children: New data on interpretability and clinical usefulness.

Author

Barbarot, S., Aubert, H., Stalder, J.‐F., Roye, S., and Delarue, A.

Subjects
*ATOPIC dermatitis, *PATIENT reported outcome measures, *RANDOMIZED controlled trials
Abstract

Background: There is limited data about the clinical meaningfulness of the Scoring of Atopic Dermatitis (SCORAD) and Patient‐Oriented SCORAD (PO‐SCORAD), particularly in children with mild‐to‐moderate AD. Regular use of patient‐reported outcomes, may deliver more accurate information about the overall health status of AD patients than routine but sparse physician assessments. Objective: To confirm the correlation between SCORAD, PO‐SCORAD, Patient‐Oriented Eczema Measure (POEM) and Investigator's Global Assessment (IGA). To evaluate the interpretability and clinical usefulness of the SCORAD and PO‐SCORAD scores in children. Methods: Data were drawn from a 12‐week randomized controlled trial in 335 children, aged 2–6 years, with mainly mild‐to‐moderate AD. Investigators captured SCORAD and IGA at each study visit. Parents used PO‐SCORAD twice‐weekly, and POEM once‐weekly. Results: There were strong correlations between PO‐SCORAD and SCORAD (r = 0.874), PO‐SCORAD and POEM (0.734) and PO‐SCORAD and IGA (0.613). The best fit ('k' statistic: 0.68) between SCORAD and IGA classes was noted for the following SCORAD categories: <12 (clear/almost clear); 12–25 (mild); and ≥25 (moderate/severe). PO‐SCORAD area under the curve over 8 weeks was significantly greater than that of SCORAD (p = 0.0002), giving a better estimate of disease severity between visits. Patients with a flare within the next 7 days had significantly higher PO‐SCORAD scores 7 days before the flare (p < 0.0001). Moderate erythema was the most significant flare predictor (p < 0.0001). Conclusion: PO‐SCORAD is robust and reliable and appears to warrant far greater utility in routine clinical practice than other scores. PO‐SCORAD, used twice‐weekly, may improve the management of patients with AD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Hyperéosinophilie associée au traitement par dupilumab dans la dermatite atopique modérée à sévère : étude rétrospective multicentrique du GREAT

Author

Marcant, P., primary, Balayé, P., additional, Merhi, R., additional, Seneschal, J., additional, Tauber, M., additional, Jendoubi, F., additional, Nosbaum, A., additional, Raison-Peyron, N., additional, Du-Thanh, A., additional, Lasek, A., additional, Ferrier le Bouedec, M.-C., additional, Tetart, F., additional, Valois, A., additional, Lefevre, G., additional, Barbarot, S., additional, Soria, A., additional, Jachiet, M., additional, and Staumont-Sallé, D., additional

Published
2020
Full Text
View/download PDF

46. Durées de traitement et post-traitement des traitements systémiques dans une cohorte nationale française d’enfants ayant une dermatite atopique

Author

Chambrelan, E., primary, Barbarot, S., additional, Bekel, L., additional, Poizeau, F., additional, Mahé, E., additional, Puzenat, E., additional, Delaunay, J., additional, Mallet, S., additional, Bessis, D., additional, Maruani, A., additional, Miquel, J., additional, Raison-Peyron, N., additional, Darrieux, L., additional, Abasq, C., additional, Phan, A., additional, Aurélie, D.-T., additional, Kupfer, I., additional, Bonniaud, B., additional, Bouzille, G., additional, Law Ping Man, S., additional, Dupuy, A., additional, and Droitcourt, C., additional

Published
2020
Full Text
View/download PDF

50. Manifestations cutanées au cours l’épidémie de COVID-19 : étude COVID-Skin de la Société française de dermatologie

Author

Guelimi, R., primary, Salle, R., additional, Dousset, L., additional, Assier, H., additional, Fourati, S., additional, Barbarot, S., additional, Boulard, C., additional, Quetier, C. Bourseau, additional, Cambon, L., additional, Cazenave, C., additional, Colin, A., additional, Kostrzewa, E., additional, Lesort, C., additional, Roy, A. Levy, additional, Lombart, F., additional, Marco-Bonnet, J., additional, Monfort, J.-B., additional, Samimi, M., additional, Tardieu, M., additional, Sbidian, E., additional, Wolkenstein, P., additional, Le Cleach, L., additional, and Beylot-Bary, M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results